Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial
Year: 2008
Type: article
Source: American Heart Journal
Author: The BARI 2D Study Group
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: BARI 2D trial, type 2 diabetes, stable coronary artery disease, early revascularization, deferred revascularization, antidiabetic therapy, insulin sensitivity, insulin therapy, cardiovascular events, baseline characteristics, angina pectoris, hyperglycemia, dyslipidemia, hypertension, obesity
Open Access status: bronze
Funders: Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Astellas Pharma US, GlaxoSmithKline, Northwestern University, Novartis Pharmaceuticals Corporation, University of Ottawa, BD, Novo Nordisk, Astellas Pharma, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences
OpenAlex ID: W2466809224
